Because NPM1 is closely related to drug-resistant bladder cancer, this study intends to explore the differential expression of CD40 in drug-resistant bladder cancer by mass spectrometry and analyze the correlation between NPM1 and CD40 in drug-resistant bladder cancer, so as to determine whether CD40 is a noninvasive biomarker that can predict the progress of bladder cancer. This evidence concerns the gene CD40 and urinary bladder carcinoma.